Global Atrial Fibrillation Devices Market to Cross $ 12.5 Bn by 2025

February 26, 2020


According to the research report titled ‘Atrial Fibrillation Devices Market Size By Products (EP Ablation Catheters {Radiofrequency, Laser, Cryoablation, Ultrasound, Microwave}, EP Diagnostic Catheters {Fixed Curve Catheters, Steerable Catheters, Advanced Mapping Catheters}, Mapping and Recording Systems, Cardiac Monitors or Implantable Loop Recorder, Access Devices, Intracardiac Echocardiography, Left Atrial Appendage Closure Devices), By End-use (Hospitals, Cardiac Centres, Ambulatory Surgical Centres) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Poland, Switzerland, Belgium, Czech Republic, Netherlands, Sweden, Hungary, Austria, Portugal, Denmark, Norway, Finland, Ireland, Turkey, China, Japan, India, Australia, South Korea, Taiwan, New Zealand, Singapore, Brazil, Argentina, Venezuela, Columbia, Mexico, South Africa, Saudi Arabia, UAE, Egypt), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025’ available with Market Study Report LLC, the global atrial fibrillation devices market is expected to surpass USD 12.5 billion by the year 2025.
 

According to the report, rising adoption of advanced technologies in tandem with availability of progressive healthcare facilities are major factors driving the atrial fibrillation devices market growth. Evolving lifestyle coupled with rising consumption of tobacco among millennial population has increased the pervasiveness of cardiovascular diseases. This factor along with growing elderly population and favorable medical reimbursement policies are further aiding the market expansion.
 

However, high cost of atrial fibrillation devices may hinder the market growth. Lack of awareness regarding the latest technology and inadequate healthcare facilities in developing regions may also inhibit the market expansion.
 

As per product type, the report states that EP ablation catheters segment is expected to grow with a CAGR of 14.4% during the period of 2019-2025, primarily due to surging preference for minimally invasive surgeries. Moreover, positive results of atrial fibrillation devices for treating permanent, persistent, and paroxysmal conditions has enhanced the adoption rate of catheter ablation systems. Adding to this, surging investments in R&D activities are fueling the segmental growth.
 

Citing end-use landscape, atrial fibrillation devices industry from hospitals segment was worth USD 2,483.4 million in the year 2018 and is presumed to expand continuously during the estimated timeframe. Treatments for atrial fibrillation are extensively conducted in hospitals. This factor along with increasing hospitalizations are boosting the growth of the segment. Additionally, rising number of multi-specialty hospitals and shifting patient preference towards hospitals over other healthcare facilities are stimulating the industry outlook.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1979116/
 

As per regional analysis, the report cites that U.S. atrial fibrillation devices industry is predicted to expand with a CAGR of 13.9% during 2019-2025. Escalating healthcare expenditure along with availability of advanced healthcare infrastructure are augmenting the demand for the product across the country.
 

On the other hand, the atrial fibrillation devices market in China was worth USD 324.7 million in the 2018. Growing occurrence of cardiovascular diseases and rising capita per income are facilitating the business scenario in China.
 

The prominent companies operating in the atrial fibrillation devices industry are Steriotaxis, Inc., Siemens Healthineers, Medtronic Plc., Johnson & Johnson (Biosense Webster), Hansen Medical, CardioFocus, Inc., Boston Scientific Corp., BIOTRONIK, Abbott Laboratories (St. Jude Medical), and AtriCure, Inc.


Frequently Asked Questions (FAQ) :

According to the report, rising adoption of advanced technologies in tandem with availability of progressive healthcare facilities are major factors driving the atrial fibrillation devices market growth. Evolving lifestyle coupled with rising consumption of tobacco among millennial population has increased the pervasiveness of cardiovascular diseases. This factor along with growing elderly population and favorable medical reimbursement policies are further aiding the market expansion.
The report states that EP ablation catheters segment is expected to grow with a CAGR of 14.4% during the period of 2019-2025, primarily due to surging preference for minimally invasive surgeries. Moreover, positive results of atrial fibrillation devices for treating permanent, persistent, and paroxysmal conditions has enhanced the adoption rate of catheter ablation systems. Adding to this, surging investments in R&D activities are fueling the segmental growth.
The report cites that U.S. atrial fibrillation devices industry is predicted to expand with a CAGR of 13.9% during 2019-2025. Escalating healthcare expenditure along with availability of advanced healthcare infrastructure are augmenting the demand for the product across the country.
The prominent companies operating in the atrial fibrillation devices market are Steriotaxis, Inc., Siemens Healthineers, Medtronic Plc., Johnson & Johnson (Biosense Webster), Hansen Medical, CardioFocus, Inc., Boston Scientific Corp., BIOTRONIK, Abbott Laboratories (St. Jude Medical), and AtriCure, Inc.